Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.53 |
| ▸ | F10 | P00742 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | CPS1 | P31327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19814038 | 0.87 | F2 (0.56) | F2F10ALDH1A1TDP1 | |
| SCHEMBL28396135 | 0.86 | F2 (0.50) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL20640311 | 0.85 | F2 (0.57) | F2F10ALDH1A1TDP1HSD11B1 | |
| SCHEMBL13368322 | 0.83 | F10 (0.73) | F2F10ALDH1A1TDP1HSD11B1 | |
| SCHEMBL21875725 | 0.83 | F2 (0.51) | F2F10ALDH1A1TDP1HSD11B1 | |
| SCHEMBL20640332 | 0.83 | F2 (0.59) | F2F10ALDH1A1TDP1HSD11B1 | |
| SCHEMBL21875724 | 0.83 | F2 (0.43) | F2F10ALDH1A1 | |
| SCHEMBL21875661 | 0.80 | F2 (0.51) | F2F10ALDH1A1TDP1 | |
| SCHEMBL20640314 | 0.76 | F2 (0.47) | F2F10ALDH1A1HSD11B1HSD17B1 | |
| SCHEMBL20640302 | 0.75 | F2 (0.55) | F2F10ALDH1A1TDP1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| EP-3652177-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2020-05-20 | — | — | EP | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | F2 4175/4885F10 4714/4885ALDH1A1 2929/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | F2 3893/4885F10 4644/4885ALDH1A1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.